Clinical trials
Chronic Heart Failure clinical trials
Below are recruiting chronic heart failure clinical trials, each written for real people, not researchers. We’re tracking 397 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06578234RecruitingPhase 4
Comparing Adenosine Doses for Heart MRI
This study will compare different doses of adenosine during a heart MRI to find the best dose for measuring blood flow to the heart muscle. It is for people with known or possible coronary artery disease or heart failure, as well as healthy volunteers.
LundAges 40 years+ - NCT06920927Recruiting
Testing an online decision aid for heart and kidney disease
This study is testing an online tool called 'My Heart and CKD' that helps people with both chronic kidney disease and heart disease make decisions about their care. The goal is to see if it is easy to use and helpful for patients and their doctors.
Calgary, AlbertaAges 18 years+ - NCT06615492Recruiting
Lung transplant study: comparing two ECMO methods
This study compares two ways of using a heart-lung machine (ECMO) during lung transplant surgery. The goal is to see if using ECMO only when needed works as well as using it for everyone. This could help reduce risks and improve recovery.
Edmonton, AlbertaAges 18 years+ - NCT06701968Recruiting
Healthy Nordic diet for heart artery health after heart attack
This study tests whether a healthy Nordic diet (like whole grains, berries, fish, and vegetables) can slow down hardening of the arteries in people who have had a heart attack or have stable chest pain. It lasts 18 months and aims to improve heart health.
UppsalaAges 50–80 - NCT07462260RecruitingPhase 2/Phase 3
Sildenafil for severe pulmonary hypertension from rheumatic valve disease
This trial tests if sildenafil can help people with severe pulmonary hypertension caused by rheumatic valvular heart disease. It aims to see if the drug improves symptoms and heart function.
Hyderābād, SindhAges 18 years+ - NCT06041581Enrolling by invitation
Insomnia treatment study for heart health
This study tests whether treating insomnia can help lower your risk for heart disease. If you have trouble sleeping and certain heart risk factors, you may be able to join.
Indianapolis, IndianaAges 40 years+ - NCT07428707RecruitingEarly Phase 1
Study of pirtobrutinib in first-line CLL/SLL
This study tests a new oral medication called pirtobrutinib in people with previously untreated CLL or SLL. Researchers will collect blood and lymph node samples to understand how the immune system responds to the drug.
Bethesda, MarylandAges 18–100 - NCT06001827Recruiting
Study of a wrap to help new dialysis access points heal
This trial tests a special wrap placed around a new arm access point for dialysis (called an AV fistula) to see if it helps the access stay healthy and work better. It is for people who need a new AV fistula for kidney dialysis.
Bullhead City, ArizonaAges 18 years+ - NCT03589729RecruitingPhase 2
Dexrazoxane to help protect the heart during blood-cancer chemo
This Phase 2 study tests dexrazoxane, a heart-protecting medicine, to reduce heart side effects from chemotherapy in people with certain blood cancers. If you qualify, you would receive dexrazoxane along with chemotherapy, and the team will monitor your heart function closely.
Houston, TexasAges 12 years+ - NCT06757647RecruitingPhase 2
Acalabrutinib for CLL/SLL patients with heart issues from ibrutinib
This trial tests a different targeted drug, acalabrutinib, for people with CLL or SLL who developed heart problems (like atrial fibrillation) while taking ibrutinib. The goal is to see if acalabrutinib can control the cancer without causing the same heart side effects.
Columbus, OhioAges 18 years+ - NCT05724121Recruiting
Study heart rhythm changes during BTK or venetoclax treatment
This observational study tracks how your heart rhythm (heartbeat pattern) changes while you take a BTK inhibitor or venetoclax. It may help doctors better understand heart rhythm risks in people receiving these cancer-related medicines.
Bethesda, MarylandAges 18–110 - NCT06398457RecruitingEarly Phase 1
Darzalex Before Stem Cell Transplant for High-Risk Graft Failure
This trial tests giving a drug called Darzalex Faspro before the usual desensitization and a stem cell transplant for people at high risk of graft failure due to donor-specific antibodies. The goal is to prevent the transplant from failing.
Baltimore, MarylandAges 18 years+ - NCT03314974RecruitingPhase 2
Stem cell transplant study for blood cancers
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
Minneapolis, MinnesotaAges Up to 60 years
Hear when a new Chronic Heart Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic heart failure?
- Yes. Clin2 currently lists 397 recruiting chronic heart failure studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic heart failure trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic heart failure trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.